The effect of hormone replacement therapy on haemostatic risk factors for cardiovascular disease

Simple item page
dc.authorscopusid6602675218
dc.authorscopusid35606878500
dc.authorscopusid7004415692
dc.authorscopusid7003740112
dc.authorscopusid6602721312
dc.contributor.authorBalkanli Kaplan P.
dc.contributor.authorSayin N.C.
dc.contributor.authorGüçer F.
dc.contributor.authorYüce M.A.
dc.contributor.authorYardim T.
dc.date.accessioned2024-06-12T10:28:13Z
dc.date.available2024-06-12T10:28:13Z
dc.date.issued2000
dc.description.abstractOBJECTIVE: The aim of this study was to evaluate cardiovascular protective effects of oral and transdermal hormone replacement therapies on haemostatic risk factors for cardiovascular disease. STUDY DESIGN: This prospective randomized open study included 50 natural or surgical postmenopausal women. Of the 50 patients, 26 received hormone replacement therapy (HRT) consisting of 17-b estradiol and Norethindrone acetate (NETA) orally and 24 transdermally. Fibrinogen, factor VII and AT-III plasma levels were measured prior to therapy and in the third month of HRT and levels were compared statistically. RESULTS: A slightly but not statistically significant decrease of the plasma fibrinogen levels was observed in both oral and transdermal group. Although Factor VII levels decreased in both groups, this was statistically significant only in the transdermal group. In the transdermal group, factor VII level decreased from 0.421±0.14 gr/L to 0.293±8.15 gr/L (p<0.0001). Although a decrease of plasma AT-III levels has been observed also in transdermal group, this was not statistically significant. CONCLUSION: Our results show that during hormone replacement therapy factor VII levels decrease significantly by transdermal administration. However AT-III levels fall significantly by oral administration. Although a decrease of plasma AT-III levels has been observed also in transdermal group, this was not statistically significant. Falling levels of factor VII and fibrinogen, which are the most important two haemostatic cardiovascular risk factors, are supporting the preventative effects of hormone replacement therapy on cardiovascular disease.en_US
dc.identifier.endpage160en_US
dc.identifier.issn1016-5126
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-0034493225en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage155en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17145
dc.identifier.volume14en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.relation.ispartofJinekoloji ve Obstetrik Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCardiovascular Disease; Haemostatic Factors; Hormone Replacement Therapy; Menopauseen_US
dc.subjectAntithrombin Iii; Blood Clotting Factor 7; Estradiol; Estradiol Plus Norethisterone Acetate; Fibrinogen; Norethisterone Acetate; Adult; Article; Cardiovascular Disease; Cardiovascular Risk; Clinical Article; Clinical Trial; Controlled Clinical Trial; Controlled Study; Female; Fibrinogen Blood Level; Heart Protection; Hemostasis; Hormone Substitution; Human; Postmenopause; Randomized Controlled Trial; Risk Factoren_US
dc.titleThe effect of hormone replacement therapy on haemostatic risk factors for cardiovascular diseaseen_US
dc.title.alternativeHormon replasmaninin kardiyovasküler hastalik hemostatik risk faktörleri üzerine etkilerien_US
dc.typeArticleen_US

Files

Collections

Scopus İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize